British Journal of Nutrition

Full Papers

Human and Clinical Nutrition

Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial

Yukio Kadookaa1 c1, Masao Satoa2, Akihiro Ogawaa1, Masaya Miyoshia1, Hiroshi Uenishia1, Hitomi Ogawaa1, Ken Ikuyamaa3, Masatoyo Kagoshimaa4 and Takashi Tsuchidaa5

a1 Milk Science Research Institute, Megmilk Snow Brand Company Limited, 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan

a2 Laboratory of Nutrition Chemistry, Faculty of Agriculture, Graduate School, Kyushu University, Fukuoka, Japan

a3 Products Development Department, Megmilk Snow Brand Company Limited, Saitama, Japan

a4 Department of Pharmacy, Faculty of Pharmacy, Iwaki Meisei University, Fukushima, Japan

a5 Yokohama Tsuchida Medical Clinic, Yokohama, Kanagawa, Japan

Abstract

Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 108 colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (106 or 107cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2–187·8 cm2). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 107, 106 or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of − 8·5 % (95 % CI − 11·9, − 5·1; P< 0·01) in the 107 dose group, and by − 8·2 % (95 % CI − 10·8, − 5·7; P< 0·01) in the 106 dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 108cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.

(Received November 20 2012)

(Revised March 05 2013)

(Accepted March 05 2013)

(Online publication April 25 2013)

Key Words:

  • Probiotics;
  • Abdominal fat;
  • Computed tomography;
  • Body composition

Correspondence

c1 Corresponding author: Y. Kadooka, email y-kadooka@meg-snow.com

Footnotes

  Abbreviations: cfu, colony-forming units; FM, fermented milk; IEC, intestinal epithelial cells; LG2055, Lactobacillus gasseri strain SBT2055; RCT, randomised controlled trial

0Comments